Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins and LDL-cholesterol lowering: an overview.

Erik Stroes1

  • 1Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. E.S.Stroes@amc.uva.nl

Current Medical Research and Opinion
|September 6, 2005
PubMed
Summary

Statins significantly reduce cardiovascular disease risk by lowering low-density lipoprotein cholesterol (LDL-C). Even individuals with normal LDL-C levels can benefit from statin therapy for cardiovascular event prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.

Journal of comparative effectiveness research·2026
Same author

Intravenous injection of lipid-free apolipoprotein A-I dampens inflammation by reprogramming macrophage function.

Cell reports·2026
Same author

Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study.

Atherosclerosis·2026
Same author

Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis.

Atherosclerosis·2025
Same author

Fuelling aortic stenosis: the integral role of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3-mediated glycolysis in Lp(a)-induced valve inflammation.

European heart journal open·2025
Same author

Targeting <i>APOC3</i> with Olezarsen in Moderate Hypertriglyceridemia.

The New England journal of medicine·2025

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Statins are a primary treatment for dyslipidemia, effectively reducing low-density lipoprotein cholesterol (LDL-C).
  • Evidence suggests statins offer cardiovascular benefits even in individuals with non-elevated LDL-C levels.
  • Studies like ASCOT and CARDS demonstrated significant cardiovascular event reduction with atorvastatin in participants with normal baseline LDL-C.

Purpose of the Study:

  • To review the efficacy of statins in patients without markedly elevated LDL-C.
  • To discuss the optimal LDL-C target for treatment.
  • To explore future strategies for dyslipidemia management.

Main Methods:

  • Review of clinical trial data, including ASCOT, CARDS, and REVERSAL.
  • Analysis of statin's impact on cardiovascular events and atherosclerosis progression.
  • Consideration of alternative and combination therapies.

Main Results:

  • Statin therapy reduces relative risk of cardiovascular disease by 24-37%.
  • Atorvastatin (10 mg/day) significantly reduced major cardiovascular events in patients with normal baseline LDL-C.
  • Intensive atorvastatin (80 mg/day) therapy halted atheroma progression in patients with established CHD.

Conclusions:

  • Statins provide substantial cardiovascular benefits, even in individuals with normal LDL-C.
  • Despite statin efficacy, a significant portion of cardiovascular events remain preventable, necessitating further research.
  • Emerging strategies include targeting C-reactive protein (CRP) and combination therapy to modulate HDL-C and LDL-C levels.

Related Experiment Videos